CG Oncology Inc (CGON) Financial

CG Oncology, Inc. is a clinical biopharmaceutical company that focuses on the development and commercialization of bladder-sparing therapies for patients with bladder cancer. The company is headquartered in Irvine, California, and currently has 113 full-time employees. It went public on January 25, 2024. The company's lead product candidate, cretostimogene grenadenorepvec (cretostimogene), is in clinical development for the treatment of non-muscle invasive bladder cancer (NMIBC). BOND-003 is a Phase III clinical trial designed to evaluate the safety and efficacy of cretostimogene as a monotherapy in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC. CORE-001 is a Phase II single-arm, open-label trial investigating cretostimogene in combination with BCG-unresponsive NMIBC. The company's pipeline also includes PIVOT-006, a Phase III trial assessing the safety and efficacy of adjuvant cretostimogene as monotherapy in intermediate-risk NMIBC patients following transurethral resection of bladder tumor (TURBT).